merck glp 1 agonist 20 Companies in Glucagon-Like Peptide-1 Agonists Market Size GLP-1 and Anesthesia: Considerations and
Description
doi: 10.1093/ajhp/zxz284

51 The insufficient trial duration and the weakened ability of higher-grade fibrosis to change, secondary to factors like weight loss, are considered the primary reasons for the lack of positive outcomes

protects heart health

In the last years, many trials failed to find a unique treatment for all HFpEF phenotypes, apart from sodium-glucose cotransporter 2 inhibitors

Patel K, Harrison SA, Elkhashab M et al (2020) Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial
